Mizuho Initiates Coverage on Pulse Biosciences (NASDAQ:PLSE)

Analysts at Mizuho initiated coverage on shares of Pulse Biosciences (NASDAQ:PLSE) in a research report issued on Friday, Marketbeat.com reports. The firm set an “outperform” rating and a $25.00 price target on the stock. Mizuho’s price target indicates a potential upside of 83.55% from the stock’s current price.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $23.50.

Pulse Biosciences Stock Up 0.5%

Shares of NASDAQ PLSE opened at $13.62 on Friday. The stock has a market capitalization of $923.00 million, a price-to-earnings ratio of -12.05 and a beta of 1.69. Pulse Biosciences has a 52 week low of $12.56 and a 52 week high of $25.00. The firm has a 50-day simple moving average of $14.08 and a 200-day simple moving average of $15.47.

Pulse Biosciences (NASDAQ:PLSE) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.02.

Hedge Funds Weigh In On Pulse Biosciences

Large investors have recently modified their holdings of the business. BNP Paribas Financial Markets grew its holdings in shares of Pulse Biosciences by 63.6% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock worth $26,000 after acquiring an additional 680 shares during the period. Alliancebernstein L.P. boosted its position in Pulse Biosciences by 6.7% during the third quarter. Alliancebernstein L.P. now owns 20,620 shares of the company’s stock worth $365,000 after purchasing an additional 1,300 shares in the last quarter. Russell Investments Group Ltd. boosted its position in Pulse Biosciences by 44.0% during the third quarter. Russell Investments Group Ltd. now owns 4,487 shares of the company’s stock worth $79,000 after purchasing an additional 1,372 shares in the last quarter. Westside Investment Management Inc. grew its holdings in Pulse Biosciences by 2.9% in the fourth quarter. Westside Investment Management Inc. now owns 66,326 shares of the company’s stock valued at $911,000 after purchasing an additional 1,886 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its position in shares of Pulse Biosciences by 275.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock valued at $44,000 after buying an additional 2,156 shares in the last quarter. 76.95% of the stock is owned by hedge funds and other institutional investors.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.